Georgia House Approves Medical Cannabis Expansion Bill

The Georgia House of Representatives passed legislation Thursday that would significantly broaden the state's medical cannabis program, adding new qualifying conditions and allowing adult patients to consume their medicine via vaporization.

Senate Bill 220, sponsored by Republican state Sen. Matt Brass, cleared the House after first being introduced in the 2024 legislative session. The measure now heads back to the Senate for consideration of House amendments.

Georgia's medical cannabis program has operated under strict limitations since its inception, restricting patients to low-THC oil products. The state currently allows cannabis oil containing no more than 5% THC for a limited set of medical conditions.

What the Bill Changes

The legislation expands both who can access medical cannabis and how they can use it. Patients aged 21 and older would gain the option to vaporize their medicine rather than being limited to oil tinctures and other non-inhalable forms.

SB 220 also adds new qualifying medical conditions to the program, though the specific conditions weren't detailed in initial reports. Georgia's current list of qualifying conditions includes cancer, ALS, seizure disorders, multiple sclerosis, Crohn's disease, mitochondrial disease, Parkinson's disease, and sickle cell disease, among others.

The expansion comes as Georgia's medical cannabis infrastructure slowly takes shape. The state awarded licenses to production companies in 2021, but delays in facility construction and regulatory approvals have pushed back the program's full implementation.

Industry Impact

Georgia's medical cannabis market remains one of the most restrictive in the nation. Unlike many states with medical programs, Georgia doesn't allow in-state cultivation by patients and maintains strict potency limits on available products.

The addition of vaporization as a consumption method could open new product categories for the state's licensed producers, who have invested millions in cultivation and processing facilities while waiting for the market to mature.

Several Georgia production companies have faced financial challenges during the extended rollout period. The program's limited patient base—estimated at around 27,000 registered users—and product restrictions have made it difficult for operators to achieve profitability.

What Happens Next

The bill returns to the state Senate, where lawmakers will need to either accept the House version or negotiate differences in conference committee. Georgia's legislative session typically runs through late March, giving lawmakers several weeks to finalize the measure.

If signed into law, the expanded program would still require regulatory implementation by the Georgia Access to Medical Cannabis Commission, which oversees licensing and compliance for the state's medical program.

The commission has faced criticism for the slow pace of program implementation, with some patient advocates arguing that Georgia's approach has been overly cautious compared to other states' medical cannabis programs.

This article is based on original reporting by ganjapreneur.com.